What is the role of angiotensin-converting enzyme inhibitors in congestive heart failure and after myocardial infarction?

Annals of Pharmacotherapy

Volumn 30, Issue 9, 1996, Pages 986-993

  Nelson, Kent M ^a,b   Yeager, Bryan F ^a,b  

^a KAISER PERMANENTE   (United States)

^b UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

CONGESTIVE HEART FAILURE; COST BENEFIT ANALYSIS; DRUG COST; HEART EJECTION FRACTION; HEART INFARCTION; HEART VENTRICLE FUNCTION; HEMODYNAMICS; MORBIDITY; MORTALITY; PRIORITY JOURNAL; REVIEW;

EID: 0029791170     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1177/106002809603000914     Document Type: Review

References (44)

1. Yusuf S, Thom T, Abbott RD. Changes in hypertension treatment and in congestive heart failure mortality in the United States. Hypertension 1989;13:174-9.
2. Cohn JN, Johnson G, Ziesche S, Cobb F, Francis G, Tristani F, et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med 1991;325: 303-10.
3. The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 1987; 316:1429-35.
4. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991;325:293-302.
5. The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 1992;327:685-91.
6. Greenberg B, Quinones MA, Koilpillai C, Limacher M, Shindler D, Benedict C, et al. Effects of long-term enalapril therapy on cardiac structure and function in patients with left ventricular dysfunction. Results of the SOLVD echocardiography substudy. Circulation 1995;91;2504-7.
7. Northridge DN, Rose E, Raftery ED, Lahiri A, Elder AT, Shaw TRD, et al. A multicentre, double-blind, placebo-controlled trial of quinapril in mild, chronic heart failure. Eur Heart J 1993;14:403-9.
8. Giles TD, Katz R, Sullivan JM, Wolfson P, Haugland M, Kirlin P, et al. Short- and long-acting angiotensin-converting enzyme inhibitors: a randomized trial of lisinopril versus captopril in the treatment of congestive heart failure. J Am Coll Cardiol 1989;13:1240-7.
9. Colfer HT, Ribner HS, Gradman A, Hughes V, Kapoor A, Laidlaw JC, for the Benazepril Heart Failure Study Group. Effects of once-daily benazepril therapy on exercise tolerance and manifestations of chronic congestive heart failure. Am J Cardiol 1992;70:354-8.
10. Brown EJ. Effects of fosinopril on exercise tolerance and clinical deterioration in patients with chronic congestive heart failure not taking digitalis. Am J Cardiol 1995;75:596-600.
11. Packer M. Why do the kidneys release renin in patients with congestive heart failure? A nephrocentric view of converting-enzyme inhibition. Am J Cardiol 1987;60:179-84.
12. McKelvie R, McConachie D, Yusuf S. Role of angiotensin converting enzyme inhibitors in patients with left ventricular dysfunction and congestive heart failure. Eur Heart J 1994;15(suppl B):9-13.
13. Young JB. Angiotensin-converting enzyme inhibitors in heart failure: new strategies justified by recent clinical trials. Int J Cardiol 1994;43: 151-63.
14. Cleland JGF. The clinical course of heart failure and its modification by ACE inhibitors: insights from recent clinical trials. Eur Heart J 1994;15: 125-30.
15. Pouleur H, Konstam MA, van Eyll C, Melin J, Gallagher P, Yusuf S, et al., for the SOLVD Investigators. Long-term effects of enalapril on left ventricular diastolic properties: evidence for 'reversed remodelling.' Circulation 1992;86(suppl I):I-120.
16. St John Sutton M, Pfeffer MA, Plappert T, Rouleau JL, Moye LA, Dagenais GR, et al. Quantitative 2D echocardiography is a major prognostic factor for survival following myocardial infarction (abstract). Circulation 1991;84(suppl II):II-66.
17. Pflugfelder PW, Baird MG, Tonkon MJ, DiBianco R, Pitt B. Clinical consequences of angiotensin-converting enzyme inhibitor withdrawal in chronic heart failure: a double-blind, placebo-controlled study of quinapril. J Am Coll Cardiol 1993;22:1557-63.
18. Cleland JGF, Poole-Wilson PA. ACE inhibitors for heart failure: a question of dose. Br Heart J 1994;72(suppl):S106-10.
19. Kleber FX, Niemoller L, Doering W. Impact of converting-enzyme inhibition on progression of chronic heart failure: results of the Munich mild heart failure trial. BMJ 1992;67:289-96.
20. Pfeffer MA, Braunwald E, Moye LA, Basta L, Brown EJ, Cuddy TE, et al. on behalf of the SAVE Investigators. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the Survival and Ventricular Enlargement (SAVE) Trial. N Engl J Med 1992;327:669-77.
21. Davis R, Ribner HS, Keung E, Sonnenblick EH, LeJemtel TH. Treatment of chronic congestive heart failure with captopril, an oral inhibitor of angiotensin-converting enzyme. N Engl J Med 1979;301:117-21.
22. Wilson PAP. When to start an ACE inhibitor and in whom. Cardiovasc Drugs Ther 1994;8:111-4.
23. Francis GS, Rucinska EJ. Long-term effects of a once-a-day versus twice-a-day regimen of enalapril for congestive heart failure. Am J Cardiol 1989;63(suppl):17D-21D.
24. Paul SD, Kuntz KM, Eagle KA, Weinstein MC. Costs and effectiveness of angiotensin converting enzyme inhibition in patients with congestive heart failure. Arch Intern Med 1994;154:1143-9.
25. Garg R, Yusuf S, for the Collaborative Group on ACE Inhibitor Trials. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. JAMA 1995;273:1450-6.
26. Lamas GA, Pfeffer MA. Left ventricular remodeling after acute myocardial infarction: clinical course and beneficial effects of angiotensin-converting enzyme inhibition. Am Heart J 1991;121:1194-202.
27. White HD, Norris RM, Brown MA, Brandt PWT, Whitlock RML, Wild CJ. Left ventricular end-systolic volume as the major determinant of survival after recovery from myocardial infarction. Circulation 1987;76:44-51.
28. Grinstead WC, Young JB. The myocardial renin-angiotensin system: existence, importance, and clinical implications. Am Heart J 1992;123: 1039-45.
29. Young JB. Heart failure, ventricular remodelling and the renin-angiotensin system: insights from recently completed clinical trials. Eur Heart J 1993;14(suppl C):14-7.
30. Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 1993;342:821-8.
31. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardio. GISSI-3: effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Lancet 1994;343:1115-22.
32. ISIS-4 Collaborative Group. ISIS-4: a randomized factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction. Lancet 1995;345:669-85.
33. Ambrosioni E, Borghi C, Magnani B, for the Survival of Myocardial Infarction Long-Term Evaluation (SMILE) Study Investigators. The effect of the angiotensin-converting-enzyme inhibitor zofenopril on mortality and morbidity after anterior myocardial infarction. N Engl J Med 1995; 332:80-5.
34. Swedberg K, Held P, Kjekshus J, Rasmussen K, Rydén L, Wedel H, on behalf of the CONSENSUS II Study Group. Effects of the early administration of enalapril on mortality in patients with acute myocardial infarction. N Engl J Med 1992;327:678-84.
35. Sharpe N. Angiotensin-converting enzyme inhibitors in heart failure: a role after myocardial infarction. J Cardiovasc Pharmacol 1991;18(suppl 2):S99-104.
36. Francis GS. Neuroendocrine activity in congestive heart failure. Am J Cardiol 1990;66(suppl):33D-9D.
37. Borghi CB, Boschi S, Ambrosioni E, Melandri G, Branzi A, Magnani B. Evidence of a partial escape of renin-angiotensin-aldosterone blockade in patients with acute myocardial infarction treated with ACE inhibitors. J Clin Pharmacol 1993;33:40-5.
38. Bonarjee VVS, Castensen S, Caidahl K, Nilsen DWT, Edner M, Berning J, on behalf of the CONSENSUS II Multi-Echo Study Group. Attenuation of left ventricular dilatation after acute myocardial infarction by early initiation of enalapril therapy. Am J Cardiol 1993;72:1004-9.
39. Gruppo Italiano per lo Studio della Sopravvivenza nell' Infarto Miocardio. Six-month effects of early treatment with lisinopril and transdermal glyceryl trinitrate singly and together withdrawn six weeks after acute myocardial infarction: the GISSI-3 trial. J Am Coll Cardiol 1996;27:337-44.
40. Cody RJ. Comparing angiotensin-converting enzyme inhibitor trial results in patients with acute myocardial infarction. Arch Intern Med 1994;154:2029-36.
41. Ray S, Dargie H. Infarct-related heart failure: the choice of agent does not matter (editorial). Cardiovasc Drugs Ther 1994;8:433-6.
42. Wright RA, Flapan AD, Alberti KGMM, Ludlam CA, Fox KAA. Effects of captopril therapy on endogenous fibrinolysis in men with recent, uncomplicated myocardial infarction. J Am Coll Cardiol 1994;24:67-73.
43. Søgaard P, Gøtzsche C, Ravkilde J, Nørgaard A, Thygesen K. Ventricular arrhythmias in the acute and chronic phases after acute myocardial infarction: effect of intervention with captopril. Circulation 1994;90:101-7.
44. Kingma JH, van Gilst WH, Peels CH, Dambrink JHE, Verbeugt FWA, Wielenga RP, for the CATS investigators. Acute intervention with captopril during thrombolysis in patients with first anterior myocardial infarction. Results from the Captopril and Thrombolysis Study (CATS). Eur Heart J 1994;15:898-907.